Malaria vaccine shows positive initial trial results

The results of an initial Phase I clinical trial for a malaria vaccine developed by Sanaria showed that the vaccine is both safe and potent.

The positive results, recently published online in an issue of the journal Science, showed Sanaria’s PfSPZ vaccine to be effective in a human study.

The study was conducted on 80 healthy volunteers. More clinical trials are now expected in the United States and Africa.

"This is the first indication that a highly effective malaria vaccine may be available that can be used to eliminate Plasmodium falciparum malaria in geographically defined areas and prevent malaria in travelers," Dr. Fred Binka, the dean of the School of Public Health of the University of Ghana, said,.

Sanaria used a unique manufacturing process to produce the vaccine, which is composed of attenuated malaria sporozoites that are in the stage when transmitted to humans by mosquitoes. It had long been considered impossible to manufacture a sporozoite vaccine that could meet regulatory standards.

“Despite the high level protection induced by sporozoites administered by mosquito bite, before the breakthroughs reported in the Science paper, no human had ever been immunized with a sporozoite vaccine administered by needle and syringe," Dr. Stephen L. Hoffman, Sanaria's chief executive and scientific officer, said.